Thiazolidinedione

DRUG5 trials

Sponsors

Sanofi, University of Wisconsin, Madison, Stanford University, GlaxoSmithKline, Chong Kun Dang Pharmaceutical

Conditions

Diabetes MellitusDiabetes Mellitus, Type 2Insulin ResistanceMetabolic SyndromeObesityType 1 Diabetes

Phase 1

Islet Transplantation in Type 1 Diabetic Patients

CompletedNCT00214253

University of Wisconsin, MadisonType 1 Diabetes

Start: 2002-02-28End: 2011-10-31Updated: 2017-03-31

Integrating the Genetic and Metabolic Faces of Obesity

CompletedNCT00285844

Stanford UniversityInsulin Resistance, Metabolic Syndrome, Obesity

Start: 2005-10-31End: 2012-10-31Updated: 2024-12-04

Phase 3

Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment

CompletedNCT00046462

SanofiDiabetes Mellitus

Start: 2001-11-30End: 2004-12-31Target: 240Updated: 2011-01-11

A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus

CompletedNCT01777282

GlaxoSmithKlineDiabetes Mellitus

Start: 2013-02-23End: 2015-01-27Updated: 2017-05-03

Unknown Phase

Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes

RecruitingNCT06838286

Chong Kun Dang PharmaceuticalDiabetes Mellitus, Type 2

Start: 2024-03-16End: 2029-12-31Target: 10000Updated: 2025-02-20

Related Papers

Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs.

2016-12-216 citations

Inflammation in subcutaneous adipose tissue: relationship to adipose cell size.

2009-10-0980 citations